- Home
- EQR vs TEVA Comparison
EQR vs TEVA Comparison
Compare EQR & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- TEVA
- Stock Information
- Founded
- EQR 1993
- TEVA 1901
- Country
- EQR United States
- TEVA Israel
- Employees
- EQR N/A
- TEVA N/A
- Industry
- EQR Real Estate Investment Trusts
- TEVA Biotechnology: Pharmaceutical Preparations
- Sector
- EQR Real Estate
- TEVA Health Care
- Exchange
- EQR Nasdaq
- TEVA Nasdaq
- Market Cap
- EQR 24.5B
- TEVA 21.2B
- IPO Year
- EQR 1993
- TEVA N/A
- Fundamental
- Price
- EQR $59.40
- TEVA $25.58
- Analyst Decision
- EQR Buy
- TEVA Strong Buy
- Analyst Count
- EQR 11
- TEVA 7
- Target Price
- EQR $71.27
- TEVA $25.86
- AVG Volume (30 Days)
- EQR 2.9M
- TEVA 13.1M
- Earning Date
- EQR 10-28-2025
- TEVA 11-05-2025
- Dividend Yield
- EQR 4.67%
- TEVA N/A
- EPS Growth
- EQR 24.49
- TEVA N/A
- EPS
- EQR 3.03
- TEVA 0.62
- Revenue
- EQR $3,078,827,000.00
- TEVA $16,776,000,000.00
- Revenue This Year
- EQR $5.00
- TEVA $4.11
- Revenue Next Year
- EQR $3.68
- TEVA $0.40
- P/E Ratio
- EQR $19.54
- TEVA $41.86
- Revenue Growth
- EQR 4.69
- TEVA 0.02
- 52 Week Low
- EQR $58.38
- TEVA $12.47
- 52 Week High
- EQR $78.32
- TEVA $26.38
- Technical
- Relative Strength Index (RSI)
- EQR 40.36
- TEVA 78.68
- Support Level
- EQR $59.06
- TEVA $23.61
- Resistance Level
- EQR $60.57
- TEVA $26.38
- Average True Range (ATR)
- EQR 1.26
- TEVA 0.83
- MACD
- EQR 0.03
- TEVA 0.46
- Stochastic Oscillator
- EQR 18.74
- TEVA 88.60
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.